<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 10, 2025</title>
<meta name="color-scheme" content="light" />
<style>
  :root { --maxw: 800px; color-scheme: light; }
  html { -webkit-text-size-adjust: 100%; }
  body {
    margin: 0;
    padding: 0;
    background-color: #ffffff;
    color: #111111;
    font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;
    line-height: 1.6;
    font-size: 18px;
  }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

Los <span title="bispecific">anticuerpos biespecíficos</span> que <span title="activate T lymphocytes">activan linfocitos T</span> ahora <span title="are used earlier">se usan más temprano</span> en la <span title="acute lymphoblastic leukemia">leucemia linfoblástica aguda</span> (LLA) pediátrica, <span title="not only after">no solo después de</span> la <span title="relapse">recaída</span>. Nuevos <span title="phase 2–3 data">datos de fases 2–3</span> y <span title="regulatory actions">acciones regulatorias</span> en 2024 <span title="show that">muestran que</span> algunos <span title="high-risk groups">grupos de alto riesgo</span> <span title="may need">pueden necesitar</span> menos <span title="prolonged and intense chemotherapy">quimioterapia prolongada e intensa</span>.

1) En la LLA de <span title="high-risk B cells">células B de alto riesgo</span>, el <span title="COG AALL1731 study">estudio COG AALL1731</span> (NCT03914625) <span title="showed that">mostró que</span> <span title="adding blinatumomab">agregar blinatumomab</span> en la <span title="consolidation">consolidación</span> y/o <span title="post-consolidation">post-consolidación</span> <span title="gave better disease-free survival">dio mejor supervivencia libre de enfermedad</span> y <span title="better minimal residual disease responses">mejores respuestas de enfermedad mínima residual</span> (EMR) que la <span title="chemotherapy alone">quimioterapia sola</span>, <span title="with less toxicity">con menos toxicidad</span> (Brown et al., ASH 2023).

2) La FDA de EE. UU. en 2024 <span title="expanded the approval">amplió la aprobación</span> de blinatumomab para <span title="adults and pediatric patients">adultos y pacientes pediátricos</span> con LLA de <span title="CD19-positive B-cell precursors">precursores de células B CD19-positivas</span> en <span title="first or second complete remission">primera o segunda remisión completa</span> con <span title="MRD ≥0.01%">EMR ≥0.01%</span>.

3) Blinatumomab ahora <span title="is used from the start">se usa desde el inicio</span> como <span title="MRD-guided therapy">terapia dirigida por EMR</span> para <span title="convert high-risk or early slow responders">convertir a pacientes de alto riesgo o con respuesta lenta temprana</span> a <span title="MRD negative">EMR negativa</span>. Esto <span title="may allow doctors">puede permitir a los médicos</span> <span title="reduce additional intensive chemotherapy">reducir la quimioterapia intensiva adicional</span> y, <span title="sometimes">en ocasiones</span>, <span title="avoid allogeneic hematopoietic cell transplant">evitar el trasplante alogénico de células hematopoyéticas</span> (TCH).

4) Los <span title="safety data">datos de seguridad</span> <span title="show the expected">muestran las</span> <span title="neurological and cytokine release toxicities">toxicidades neurológicas y por liberación de citocinas</span> esperadas. Estas <span title="are usually manageable">suelen ser manejables</span> y, <span title="often less severe">a menudo, menos graves</span> que con <span title="CD19 CAR-T">CAR-T CD19</span>. La <span title="stepwise dosing">dosificación escalonada</span>, la <span title="close monitoring">monitorización estrecha</span> en los <span title="first cycles">primeros ciclos</span> y los <span title="rapid interruption/steroid protocols">protocolos de interrupción rápida/esteroides</span> <span title="remain very important">siguen siendo muy importantes</span>.

5) En la <span title="relapsed/refractory B-ALL">LLA B recaída/refractaria</span>, blinatumomab <span title="remains a good option">sigue siendo una buena opción</span> como <span title="bridge to transplant or CAR-T">puente al trasplante o CAR-T</span>. Nuevos <span title="CD19xCD3 bispecific antibodies">anticuerpos biespecíficos CD19xCD3</span> y <span title="trispecific antibodies">trispecíficos</span> <span title="are in initial pediatric studies">están en estudios pediátricos iniciales</span> y <span title="could make treatment easier and safer">podrían facilitar y hacer más seguro el tratamiento</span>.

Implicación: Los <span title="pediatric oncologists">oncólogos pediátricos</span> <span title="should plan to use">deben planear usar</span> <span title="CD19-targeted bispecifics">biespecíficos dirigidos a CD19</span>, <span title="mainly blinatumomab">principalmente blinatumomab</span>, como <span title="part of first-line care">parte de la atención de primera línea</span> de la LLA de células B <span title="guided by MRD">guiada por EMR</span> y <span title="reconsider how intense">reconsiderar cuán intensos</span> <span title="chemotherapy and HCT should be">deben ser la quimioterapia y el TCH</span> en <span title="high-risk patients">pacientes de alto riesgo</span>.

---
DIALOGUE

Narrator: <span title="This is a consultation">Esta es una consulta</span> para un <span title="child with high-risk B-cell acute lymphoblastic leukemia">niño con leucemia linfoblástica aguda de células B de alto riesgo</span>.
Physician: Hola, <span title="I am your doctor">soy su médico</span>. Hoy <span title="we are going to talk about">vamos a hablar sobre</span> su <span title="treatment for leukemia">tratamiento para la leucemia</span>.
Patient: Hola, doctor. <span title="I feel a little scared">Me siento un poco asustado</span>.
Physician: <span title="That is normal">Es normal</span>. Ahora <span title="we have some new medicines">tenemos algunos medicamentos nuevos</span>. <span title="They help fight">Ayudan a combatir</span> las <span title="leukemia cells">células de la leucemia</span>.
Patient: <span title="Are these medicines like chemotherapy?">¿Estos medicamentos son como la quimioterapia?</span>
Physician: Este medicamento <span title="is called blinatumomab">se llama blinatumomab</span>. <span title="It helps your T lymphocytes">Ayuda a que los linfocitos T de su cuerpo</span> <span title="find and destroy">encuentren y destruyan</span> las células de la leucemia.
Patient: <span title="Will I still need a lot of chemotherapy?">¿Todavía necesitaré mucha quimioterapia?</span>
Physician: <span title="Sometimes, with blinatumomab">A veces, con blinatumomab</span>, <span title="we can use">podemos usar</span> una <span title="less strong chemotherapy">quimioterapia menos fuerte</span>. <span title="It can be safer for you">Puede ser más seguro para usted</span>.
Patient: <span title="How do you give me this medicine?">¿Cómo me administran este medicamento?</span>
Physician: <span title="It is given through the vein">Se administra por la vena</span> en el hospital. <span title="We watch you very closely">Lo vigilamos muy de cerca</span> los <span title="first days">primeros días</span>.
Patient: <span title="Is it going to make me feel very bad?">¿Me va a hacer sentir muy mal?</span>
Physician: <span title="You may have fever">Puede tener fiebre</span>, <span title="headache">dolor de cabeza</span> o <span title="feel tired">sentirse cansado</span>. <span title="We can treat most side effects quickly">Podemos tratar la mayoría de los efectos secundarios rápidamente</span>.
Patient: <span title="Can this medicine help me get better?">¿Este medicamento puede ayudarme a mejorar?</span>
Physician: Sí, <span title="it can reduce the leukemia cells">puede reducir las células de la leucemia</span> en su cuerpo. <span title="It helps many patients">Ayuda a muchos pacientes</span> a <span title="become MRD-negative">volverse EMR-negativos</span>.
Patient: <span title="Thank you, doctor. I want to try it">Gracias, doctor. Quiero intentarlo</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Bispecific T-cell–engaging antibodies are now used earlier in pediatric acute lymphoblastic leukemia (ALL), not only after relapse. New phase 2–3 data and 2024 regulatory actions show some high-risk groups may need less long, hard chemotherapy.

1) In high-risk B-cell ALL, the COG AALL1731 trial (NCT03914625) showed that adding blinatumomab in consolidation and/or post-consolidation gave better disease-free survival and better MRD responses than chemotherapy alone, with less toxicity (Brown et al., ASH 2023).

2) The US FDA in 2024 expanded blinatumomab approval for adults and pediatric patients with CD19-positive B-cell precursor ALL in first or second complete remission with MRD ≥0.01%.

3) Blinatumomab is now used upfront as MRD-directed therapy to change high-risk or slow early responders to MRD-negative. This may let clinicians lower extra intensive chemotherapy and sometimes avoid allogeneic HSCT.

4) Safety data show expected neurologic and cytokine-release toxicities. These are usually manageable and often less severe than with CD19 CAR-T. Step-up dosing, close early-cycle monitoring, and fast interruption/steroid protocols are still very important.

5) In relapsed/refractory B-ALL, blinatumomab is still a good bridge to transplant or CAR-T. New CD19xCD3 bispecifics and trispecific antibodies are in early pediatric trials and may make treatment easier and safer.

Implication: Pediatric oncologists should plan to use CD19-directed bispecifics, mainly blinatumomab, as MRD-driven parts of frontline B-cell ALL care and rethink how strong chemotherapy and HSCT must be in high-risk patients.

---
DIALOGUE

Narrator: This is a clinic visit for a child with high-risk B-cell acute lymphoblastic leukemia. 
Physician: Hello, I am your doctor. Today, we will talk about your leukemia treatment. 
Patient: Hello, Doctor. I feel a bit scared. 
Physician: That is normal. We have some new medicines now. They help fight leukemia cells. 
Patient: Are these medicines like chemotherapy? 
Physician: This medicine is called blinatumomab. It helps your body’s T-cells find and kill leukemia cells. 
Patient: Will I still need a lot of chemotherapy?
Physician: Sometimes, with blinatumomab, we can use less strong chemotherapy. It can be safer for you. 
Patient: How do I get this medicine?
Physician: It is given in your vein in the hospital. We watch you very closely for the first days. 
Patient: Will it make me very sick?
Physician: You may have fever, headache, or feel tired. We can treat most side effects quickly. 
Patient: Can this medicine help me get better?
Physician: Yes, it can lower leukemia cells in your body. It helps many patients become MRD-negative. 
Patient: Thank you, Doctor. I want to try it.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 10, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>